KYTX: Kyverna Therapeutics, Inc.
Performance
KYTX -21.43%
Watchlist
Select an item
Summary
KYTX at a glance
KYTX returned -21.43% over the past year. Its worst drop in that year was -59.02%, smaller than 13% of stocks on Redstone, and its Sharpe ratio of 0.14 beats 33% of stocks on Redstone. It pays no dividends.
Current Drawdown
-54.04%
Rolling Volatility
77.10%
Actions
Metrics
Risk Indicators
Alpha-9.29%
Beta2.14x
Sharpe0.14
Sortino0.19
Omega1.02
Calmar-0.36
Martin0.42
Profile
About KYTX
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $320M
- Listed
- Feb 2024
- Employees
- 149
- Headquarters
- Emeryville, CA
- Website
- kyvernatx.com
Comparisons